Hereditary haemorrhagic telangiectasia: A rare disease as a model for the study of human atherosclerosis

Current Pharmaceutical Design

Volumn 13, Issue 36, 2007, Pages 3656-3664

  Lenato, G M ^a   Suppressa, P ^a   Giordano, P ^a   Guanti, G ^a   Guastamacchia, E ^a   Triggiani, V ^a   Amati, L ^b   Resta, F ^a   Covelli, V ^c   Jirillo, E ^a,b   Sabba C ^a  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^c POLICLINICO   (Italy)

Author keywords

Atherosclerosis; Endoglin; Endothelial cells; Hereditary haemorrhagic telangiectasia; Transforming growth factor beta

Indexed keywords

ENDOGLIN; PROTEIN ALK1; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTERIOVENOUS MALFORMATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOSOMAL DOMINANT DISORDER; CELL METABOLISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPISTAXIS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENDU OSLER WEBER DISEASE; REVIEW; TELANGIECTASIA;

ACTIVIN RECEPTORS, TYPE II; ADOLESCENT; ANTIGENS, CD; ATHEROSCLEROSIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOKINES; HUMANS; IMMUNITY, NATURAL; IMMUNOPHENOTYPING; INFANT; LEUKOCYTES, MONONUCLEAR; MUTATION; PHAGOCYTES; RECEPTORS, CELL SURFACE; RESPIRATORY BURST; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 37449028959     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207783018572     Document Type: Review

References (51)

1. Guttmacher AE, Marchuk DA, White RJ. Hereditary hemorrhagic telangiectasia N Engl J Med 1995; 33: 918-24.
2. Sabbià C. A rare and misdiagnosed bleeding disorder: hereditary hemorrhagic telangiectasia. J Thromb Haemost 2005; 3: 1-10
3. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
4. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-β binding protein of endothelial cells is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994 8: 345-51
5. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nature Genet 1996; 13: 189-95.
6. Cole SG, Begbie ME, Wallace GMF, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42: 577-82.
7. Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, Tuncali T, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet 2006; 140A: 2155-62.
8. Gallione CJ, Richards JA, Letteboer TG, Rushlow D, Prigoda NL, Leedom TP, et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006; 43: 793-7.
9. Fernandez-Lopez A, Sanz-Rodriguez F, Blanco FJ, Bernabeu C, Botella LM. Hereditary haemorrhagic telangiectasia, a vascular dysplasia affecting TGF-β signalling pathway. Clin Med Res 2006; 4: 66-78.
10. Lenato GM, Guanti G. Hereditary haemorrhagic telangiectasia: genetic and molecular aspects. Curr Pharm Des 2006; 12: 1173-93.
11. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000; 12: 235-43.
12. van Laake LW, van den Driesche S, Post S, FeiJen A, Jansen MA, Driessens MR, et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 2006; 114: 2288-97.
13. Post S, Smits A, Sluijter J, Hoefer I, Snijder RJ, Mager JJ, et al. A disturbed cxcr4/cd26 balance in endoglin deficient mononuclear cells results in impaired homing. Proceedings of VIIth International Scientific HHT Conference, Abstract nr 22, Hematology Meeting Reports 2007; 1: 8-9
14. Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena J, et al. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc Res 2006; 69: 845-54.
15. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelnan DH, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary haemorrhagic telangiectasia. Circ Res 2005; 96: 684-96.
16. O'Brien ER, Bennett KL, Garvin MR, Zderic TW, Hinohara T, Simpson JB, et al. Big-h3, a transforming growth factor-β-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions. Arterioscler Thromb Vase Biol 1996; 16: 576-84.
17. Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, et al. Distinct Patterns of Transforming Growth Factor-ß isoform and receptor expression in human atherosclerotic lesions: colocalization implicates tgf-ß in fibrofatty lesion development. Circulation 1999; 99: 2883-91.
18. Kalinina N, Agrotis A, Antropova Y, Ilyinskaya O, Smirnov V, Tararak E, et al. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-ß/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vase Biol 2004; 24: 1391-6.
19. Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M, et al. Endoglin is overexpressed after arterial injury and is required for Transforming Growth Factor-ß-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vase Biol 2000; 20: 2546-52.
20. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CPH. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000; 153: 323-35.
21. Amati L, Passeri ME, Resta F, Triggiani M, Jirillo E, Sabbà C. Ablation of T-Helper 1 cell derived cytokines and of monocyte-derived tumor necrosis factor-α in hereditary hemorrhagic teleangiectasia: Immunological consequences and clinical considerations. Curr Pharm Des 2006; 12: 1201-8.
22. Cirulli A, Loria MP, Dambra P, Mangialardi G, Di Serio F, Ventura MT, et al. Patients with hereditary hemorrhagic telangectasia (HHT) exhibit a deficit of polymorphonuclear cell and monocyte oxidative burst and pbagocytosis: a possible correlation with altered adaptive immune responsiveness in HHT. Curr Pharm Des 2006; 12: 1209-15.
23. Giordano P, Nigro A, Lenato GM, Guanti G, Suppressa P, Lastella P, et al. Screening for children from families with Rendu-Osler-Weber disease: from geneticist to clinician. J Thromb Haemost 2006; 4: 1237-45.
24. Mancini ML, Verdi JM, Conley BA, Oxburgh L, Nicola T, Vary CPH. Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev Biol 2007; 308: 520-33.
25. Bockman DE, Kirby ML. Neural crest interactions in the development of the mumme system. J Immunol 1985; 135: 766.
26. Boehm T, Bleul CC. Thymus - Homing precursors and the thyimic microenviromnent. Trends Immunol 2006; 27: 477-84.
27. Dupuis-Girod S, Giraud S, Decullier E, Lesca G, Cottin V, Faure F, et al. Hemorrhagic hereditary telangiectasia (Rendu-Osler Disease) and infectious diseases: an underestimated association. Clin Inf Dis 2007; 44: 841-5.
28. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vase Biol 1995; 15: 551-61.
29. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
30. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362. 801-9.
31. McCaffrey TA, Du B, Consigh S, Szabo P, Bray PJ, Hartner L, et al. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 1997; 100: 2182-8.
32. Chen J-K, Hoshi H, McKeehan WL. Transforming growth factor type β specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc Natl Acad Sci USA 1987; 84: 5287-91.
33. Falcone DJ, McCaffrey TA, Mathew J, McAdam K, Borth W. THP-1 macrophage membrane-bound plasmin activity is upregulated by transforming growth factor-β1 via increased expression of urokinase and the urokinase receptor. J Cell Physiol 1995; 164: 334-43.
34. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993; 204: 356-63
35. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis.Proc Natl Acad Sci USA 2000; 14: 2626-31.
36. Seki T, Hong KH, Oh SP. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest 2006; 86: 116-29.
37. Bobik A. Transforming growth factor-ßs and vascular disorders. Arterioscler Thromb Vase Biol 2006; 26: 1712-20.
38. Jirillo E, Amati L, Suppressa P, Cirimele D, Guastamacchia E, Covelli V, et al. Involvement of the transforming growth factor β in the pathogenesis of hereditary hemorrhagic teleangiectasia. Curr Pharm Des 2006; 12: 1195-200.
39. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor- β1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-9.
40. Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12:171-81.
41. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, et al. Endoglin modulates cellular responses to TGF-ß1. J Cell Biol 1996; 133: 1109-21.
42. Schmidt-Weber CB, Letarte M, Kunzmann S, Ruckert B, Bernabeu C, Blaser K. TGFβ signalling of human T cells is modulated by the ancillary TGFβ receptor endoglin. Int Immun 2005; 17: 921-30.
43. Sanz-Rodriguez F, Fernandez-Lopez, A, Zarrabeitia R, Perez-Molino A, Ramírez JR, Coto E, et al. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia. Deficient endoglin upregulation in activated monocytes. Clin Chem 2004; 279: 32858-68.
44. Fernandez-Lopez A, Sanz-Rodrigucz F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, et al. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of endoglin and ALK1. Hum Mutat 2006; 27: 295.
45. Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des 2006; 12: 4229-45.
46. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-β in T cells accelerates atherosclerosis. J Clin Invest 2003; 112: 1342-50.
47. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan Activin Receptor-Like Kinase 1 (ALK1) in endothelial cells. Blood 2007; 109:1953-61.
48. Piao M, Tokunaga, O. Significant expression of endoglin (CD105), TGFβ-1 and TGFβR-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscl Thromb 2006; 13: 82-9.
49. Cirulli A, Loria MP, Dambra P, Di Serio F, Ventura MT, Amati L, et al. Patients with Hereditary Hemorrhagic Telangectasia (HHT) exhibit a deficit of polymorphonuclear cell and motiocyte oxidative burst and phagocytosis: a possible correlation with altered adaptive immune responsiveness in HHT. Curr Pharm Des 2006; 12(10): 1209-15.
50. Jirillo E, Amati L, Suppressa P, Cirimele D, Guastamacchia E, Covelli V, et al. Involvement of the transforming growth factor beta in the pathogenesis of hereditary hemorrhagic telangiectasia. Curr Pharm Des 2006; 12(10): 1195-200.
51. Lenato GM. and Guanti G. Hereditary Haemorrhagic Telangiectasia, (HHT): genetic and molecular aspects. Curr Pharm Des 2006; 12(10): 1173-93.